We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

HIV Combo Assay Provides Quick, Reliable Results

By LabMedica International staff writers
Posted on 12 Nov 2013
An innovative new HIV combination assay delivers accurate, reliable results more quickly, up to several days earlier than other currently available assays.

Siemens Healthcare of Siemens AG (Munich, Germany) now offers the “Enzygnost HIV Integral 4 Assay1,” an HIV test mainly intended for use in blood banks or laboratories, enabling clinicians to identify HIV infection earlier and improve patient care. It is available2 on the Siemens laboratory systems Quadriga BeFree and BEP. This assay is an HIV combination (“HIV Combo”) test, detecting both the HIV p24 antigen and HIV antibodies, and becoming the standard screening technique used in many European Union countries.

The development of the new HIV assay is an example of the company’s innovative power, one of the goals of “Agenda 2013”, an initiative of the Siemens Healthcare Sector in which specific implementation measures have been defined in four fields of action: innovation, competitiveness, regional footprint, and people development. The Enzygnost HIV Integral 4 assay delivers both excellent specificity and sensitivity. In a study of 14,169 donor samples tested at three different blood banks, initial specificity was demonstrated at 99.94%. Data also show that this assay has higher sensitivity and provides superior seroconversion performance (quicker prevalence of the antibody) compared to other currently available assays, detecting HIV infection up to 14 days earlier.

“Reliable and accurate testing technologies are critical to supporting HIV infection control and optimal patient management,” said Stefan Wolf, CEO, Hemostasis, Hematology and Specialty Business Unit, Siemens Healthcare, Diagnostics Division; "The increased sensitivity of the HIV Integral 4 assay enables clinicians to detect disease and initiate treatment earlier, and its high specificity provides our blood bank customers with confidence that the results are precise, enhancing the accuracy of their donor screening programs.”

1This product is not commercially available in all countries (e.g., not available for sale in the USA). Due to regulatory reasons, their future availability cannot be guaranteed. Details are available from local Siemens organizations.
2ibid.

Related Links:

Siemens



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Automated Blood Typing System
IH-500 NEXT
New
Hepatitis B Virus Test
HBs Ab – ELISA
New
Newborn Screening Test
NeoMass AAAC 3.0

Latest Immunology News

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival

Computational Tool Predicts Immunotherapy Outcomes for Metastatic Breast Cancer Patients